This review found no studies that assessed the effectiveness of pill-in-the-pocket. Studies that included relevant drugs for treating paroxysmal atrial fibrillation found that flecainide and propafenone had similar effectiveness relating to conversion to normal sinus rhythm up to eight hours. These conclusions should be interpreted cautiously, given the possibility of missing relevant studies and concerns over review methods.
Study selection
Randomised controlled trials (RCTs) that compared pill-in-the-pocket strategy (single oral dose) with episodic inhospital treatment (propafenone, flecainide, beta-blockers, sotalol and amiodarone) or continuous prophylactic antiarrhythmic drug therapy (propafenone, flecainide, beta blockers sotalol and amiodarone) in patients with paroxysmal atrial fibrillation were eligible for inclusion. RCTs that provided data only on a subgroup of their recruited patients were excluded. The eligible secondary comparator was radiofrequency ablation. The review outcomes were mean time to conversion and conversion rates (both of which were measured from atrial fibrillation to normal sinus rhythm) and number of hospital visits.
None of the identified studies compared pill-in-the-pocket strategy with any other treatment. Twelve RCTs identified were relevant to the decision problem as these included relevant drugs for treating paroxysmal atrial fibrillation. Drugs assessed included flecainide, propafenone, digoxin-quinidine and sotalol administered orally or intravenously. Where reported, follow-up ranged from two to 89 hours in most studies; one study reported a mean follow-up of 15 months. Studies were conducted in a hospital setting and published between 1988 and 2004.
Two reviewers independently assessed studies for inclusion.
Assessment of study quality
The authors stated that no quality assessment was performed.
Data extraction
Data were extracted on the mean and standard deviation or event rates. Data were extracted by one reviewer and checked by a second. 
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Record Status
This is a critical abstract of a systematic review that meets the criteria for inclusion on DARE. Each critical abstract contains a brief summary of the review methods, results and conclusions followed by a detailed critical assessment on the reliability of the review and the conclusions drawn.
